Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine

Locus ceruleus (LC)-supplied norepinephrine (NE) suppresses neuroinflammation in the brain. To elucidate the effect of LC degeneration and subsequent NE deficiency on Alzheimer's disease pathology, we evaluated NE effects on microglial key functions. NE stimulation of mouse microglia suppressed Aβ-induced cytokine and chemokine production and increased microglial migration and phagocytosis of Aβ. Induced degeneration of the locus ceruleus increased expression of inflammatory mediators in APP-transgenic mice and resulted in elevated Aβ deposition. In vivo laser microscopy confirmed a reduced recruitment of microglia to Aβ plaque sites and impaired microglial Aβ phagocytosis in NE-depleted APP-transgenic mice. Supplying the mice the norepinephrine precursor L-threo-DOPS restored microglial functions in NE-depleted mice. This indicates that decrease of NE in locus ceruleus projection areas facilitates the inflammatory reaction of microglial cells in AD and impairs microglial migration and phagocytosis, thereby contributing to reduced Aβ clearance. Consequently, therapies targeting microglial phagocytosis should be tested under NE depletion.

[1]  J. Leza,et al.  Astrocyte-Derived MCP-1 Mediates Neuroprotective Effects of Noradrenaline , 2009, The Journal of Neuroscience.

[2]  F. Haiss,et al.  Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance , 2008, The Journal of Neuroscience.

[3]  S. Kalinin,et al.  Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta , 2007, Journal of neurochemistry.

[4]  H. Kettenmann,et al.  Microglia: active sensor and versatile effector cells in the normal and pathologic brain , 2007, Nature Neuroscience.

[5]  M. Mesulam,et al.  Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease , 2007, Neurobiology of Aging.

[6]  M. Famulok,et al.  GGA1 Is Expressed in the Human Brain and Affects the Generation of Amyloid β-Peptide , 2006, The Journal of Neuroscience.

[7]  Mathias Hoehn,et al.  Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice , 2006, The Journal of Neuroscience.

[8]  E. Peskind,et al.  Compensatory Changes in the Noradrenergic Nervous System in the Locus Ceruleus and Hippocampus of Postmortem Subjects with Alzheimer's Disease and Dementia with Lewy Bodies , 2006, The Journal of Neuroscience.

[9]  T. Möller,et al.  The Microglia-activating Potential of Thrombin , 2004, Journal of Biological Chemistry.

[10]  S. Thomas,et al.  A Distinct Role for Norepinephrine in Memory Retrieval , 2004, Cell.

[11]  A. Rosenquist,et al.  Noradrenergic mechanisms in neurodegenerative diseases: a theory , 2004, Brain Research Reviews.

[12]  Karel Svoboda,et al.  ScanImage: Flexible software for operating laser scanning microscopes , 2003, Biomedical engineering online.

[13]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[14]  D. Feinstein,et al.  Noradrenergic regulation of inflammatory gene expression in brain , 2002, Neurochemistry International.

[15]  M. Sakanaka,et al.  Effects of norepinephrine on rat cultured microglial cells that express α1, α2, β1 and β2 adrenergic receptors , 2002, Neuropharmacology.

[16]  T. Klockgether,et al.  Noradrenergic Depletion Potentiates β-Amyloid-Induced Cortical Inflammation: Implications for Alzheimer's Disease , 2002, The Journal of Neuroscience.

[17]  M. Esiri,et al.  Noradrenergic changes, aggressive behavior, and cognition in patients with dementia , 2002, Biological Psychiatry.

[18]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[19]  D. Borchelt,et al.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. , 2001, Biomolecular engineering.

[20]  G. D’Arcangelo,et al.  The Inhibitory Effects of Interleukin‐6 on Synaptic Plasticity in the Rat Hippocampus Are Associated with an Inhibition of Mitogen‐Activated Protein Kinase ERK , 2000, Journal of neurochemistry.

[21]  A. Sher,et al.  Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion , 2000, Molecular and Cellular Biology.

[22]  L. Pradier,et al.  Impaired recovery of noradrenaline levels in apolipoprotein E-deficient mice after N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine lesion , 1999, Neuroscience.

[23]  D. Goldstein,et al.  Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer’s disease , 1999, Biological Psychiatry.

[24]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[25]  W. Kamphorst,et al.  Increased activity of surviving locus ceruleus neurons in Alzheimer's disease , 1999, Annals of neurology.

[26]  T. Hartmann,et al.  TNFα plus IFNγ induce the production of Alzheimer β‐amyloid peptides and decrease the secretion of APPs , 1999 .

[27]  R. Palmiter,et al.  Restoration of Norepinephrine and Reversal of Phenotypes in Mice Lacking Dopamine β‐Hydroxylase , 1998, Journal of neurochemistry.

[28]  J. Medina,et al.  Recovery of central noradrenergic neurons one year after the administration of the neurotoxin DSP4 , 1994, Neurochemistry International.

[29]  F. Eusebi,et al.  Tumor necrosis factor alters synaptic transmission in rat hippocampal slices , 1992, Neuroscience Letters.

[30]  J. Fritschy,et al.  Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: Compensatory response to neurotoxin‐induced cell death in the adult rat brain , 1992, The Journal of comparative neurology.

[31]  F. E. Bloom,et al.  Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type , 1983, Neuroscience Letters.

[32]  P. Yates,et al.  Changes in the Monoamine Containing Neurones of the Human Cns in Senile Dementia , 1980, British Journal of Psychiatry.

[33]  B. Winblad,et al.  Changes in the Brain Catecholamines in Patients with Dementia of Alzheimer Type , 1979, British Journal of Psychiatry.

[34]  Bo Zhang,et al.  Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors. , 2002, Neuropharmacology.

[35]  T. Hartmann,et al.  TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  R. Levy,et al.  Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease--a hypothesis. , 1994, Pharmacopsychiatry.

[37]  J. Fritschy,et al.  Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? , 1991, Progress in brain research.

[38]  M. Roth,et al.  NEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE , 1987, Alzheimer disease and associated disorders.